Table 2 Patient analysis sets and PRO data availability
Panitumumab plus BSC | BSC alone | |
|---|---|---|
Total randomised (n) | 231 | 232 |
PRO all enrolled analysis set (n) | 207 | 184 |
PRO all enrolled analysis set and alive at week 8, EQ-5D (n) | 179 | 164 |
Patients completing EQ-5D (n) | ||
Week 4 | 189 | 129 |
Week 8 | 111 | 47 |
Week 12 | 91 | 14 |
Week 16 | 62 | 7 |
PRO all enrolled analysis set and alive at week 8, FCSI (n) | 181 | 166 |
Patients completing FCSI subscale (n) | ||
Week 4 | 190 | 130 |
Week 8 | 112 | 48 |
Week 12 | 90 | 14 |
Week 16 | 62 | 7 |
